Vertex Pharmaceuticals (VRTX) Research & Development (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted Research & Development of $993.8 million for Q2 2026, up 3.35% on a QoQ basis from $961.6 million in Q1 2026, and up 1.57% year-over-year from $978.4 million in Q2 2025.
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) Research & Development (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals has reported Research & Development for 18 years, with the latest figure at $993.8 million in Q2 2026.
- On a quarterly basis, Research & Development rose 1.57% year-over-year to $993.8 million in Q2 2026; TTM through Jun 2026 was $3.9 billion, a 1.93% increase from a year earlier, with the FY2025 full-year figure at $3.9 billion, up 7.69% from the prior year.
- Research & Development was $993.8 million for Q2 2026 at Vertex Pharmaceuticals, up from $961.6 million in the prior quarter.
- The five-year high for Research & Development was $998.7 million in Q4 2024, with the low at $600.1 million in Q2 2022.
- Average Research & Development over 5 years is $844.4 million, with a median of $850.2 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 38.12% in 2022, then slipped 2.5% in 2025.
- Over 5 years, Research & Development stood at $694.1 million in 2022, then grew by 18.8% to $824.6 million in 2023, then advanced by 21.11% to $998.7 million in 2024, then declined by 2.5% to $973.7 million in 2025, then gained by 2.06% to $993.8 million in 2026.
- The last three Research & Development figures came in at $993.8 million (Q2 2026), $961.6 million (Q1 2026), and $973.7 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Bristol Myers Squibb | 124.95 Bn | 113.89 Bn | 9.25 Bn | 2.96 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 993.80 Mn |
| Mar 31, 2026 | 961.60 Mn |
| Dec 31, 2025 | 973.70 Mn |
| Sep 30, 2025 | 977.70 Mn |
| Jun 30, 2025 | 978.40 Mn |
| Mar 31, 2025 | 979.70 Mn |
| Dec 31, 2024 | 998.70 Mn |
| Sep 30, 2024 | 875.90 Mn |
| Jun 30, 2024 | 966.60 Mn |
| Mar 31, 2024 | 789.10 Mn |
| Dec 31, 2023 | 824.60 Mn |
| Sep 30, 2023 | 810.00 Mn |
| Jun 30, 2023 | 785.70 Mn |
| Mar 31, 2023 | 742.60 Mn |
| Dec 31, 2022 | 694.10 Mn |
| Sep 30, 2022 | 645.00 Mn |
| Jun 30, 2022 | 600.10 Mn |
| Mar 31, 2022 | 601.10 Mn |
| Dec 31, 2021 | 567.80 Mn |
| Sep 30, 2021 | 467.00 Mn |
API Access
Vertex Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=VRTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "VRTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=VRTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();